Gyre Therapeutics (GYRE) said its Hydronidone compound to treat liver fibrosis in patients with chronic hepatitis B met the primary endpoint in the phase 3 trial in China.
The 52-week trial revealed that almost 53% of patients receiving Hydronidone achieved 1-stage regression in liver fibrosis versus placebo, Gyre said Thursday in a statement.
The drug was well tolerated with no discontinuations due to adverse events, the company said.
Gyre plans to present full trial results at a medical congress and file a new drug application with China's National Medical Products Administration in Q3.
In a separate statement, Gyre announced a proposed underwritten public share offering with proceeds to advance its Phase 2 clinical trial of F351 in the US to treat liver fibrosis, among other things.
Gyre shares fell 15% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。